151 related articles for article (PubMed ID: 23677449)
1. Flu-like symptoms and associated immunological response following therapy with botulinum toxins.
Baizabal-Carvallo JF; Jankovic J; Feld J
Neurotox Res; 2013 Aug; 24(2):298-306. PubMed ID: 23677449
[TBL] [Abstract][Full Text] [Related]
2. Flu-like symptoms following botulinum toxin therapy.
Baizabal-Carvallo JF; Jankovic J; Pappert E
Toxicon; 2011 Jul; 58(1):1-7. PubMed ID: 21620881
[TBL] [Abstract][Full Text] [Related]
3. Can aerobic exercise alleviate flu-like symptoms following interferon beta-1a injections in patients with multiple sclerosis?
Langeskov-Christensen M; Kjølhede T; Stenager E; Jensen HB; Dalgas U
J Neurol Sci; 2016 Jun; 365():114-20. PubMed ID: 27206886
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical evidence suggests repeated intravesical application of botulinum toxin A injections may improve treatment efficacy of interstitial cystitis/bladder pain syndrome.
Shie JH; Liu HT; Wang YS; Kuo HC
BJU Int; 2013 Apr; 111(4):638-46. PubMed ID: 22943596
[TBL] [Abstract][Full Text] [Related]
5. Cervical dystonia: factors deteriorating patient satisfaction of long-term treatment with botulinum toxin.
Marciniec M; Szczepańska-Szerej A; Rejdak K
Neurol Res; 2020 Nov; 42(11):987-991. PubMed ID: 32693754
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of botulinum toxin injections in dystonia.
Ramirez-Castaneda J; Jankovic J
Toxins (Basel); 2013 Feb; 5(2):249-66. PubMed ID: 23381141
[TBL] [Abstract][Full Text] [Related]
7. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease.
Guidubaldi A; Fasano A; Ialongo T; Piano C; Pompili M; Mascianà R; Siciliani L; Sabatelli M; Bentivoglio AR
Mov Disord; 2011 Feb; 26(2):313-9. PubMed ID: 21259343
[TBL] [Abstract][Full Text] [Related]
8. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B.
Oshima M; Deitiker PR; Jankovic J; Duane DD; Aoki KR; Atassi MZ
J Neuroimmunol; 2011 Dec; 240-241():121-8. PubMed ID: 22079193
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
Brashear A; Lew MF; Dykstra DD; Comella CL; Factor SA; Rodnitzky RL; Trosch R; Singer C; Brin MF; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1439-46. PubMed ID: 10534248
[TBL] [Abstract][Full Text] [Related]
10. Perspective of an International Online Patient and Caregiver Community on the Burden of Spasticity and Impact of Botulinum Neurotoxin Therapy: Survey Study.
Patel AT; Wein T; Bahroo LB; Wilczynski O; Rios CD; Murie-Fernández M
JMIR Public Health Surveill; 2020 Dec; 6(4):e17928. PubMed ID: 33284124
[TBL] [Abstract][Full Text] [Related]
11. Dose titration of intramuscular interferon beta-1a reduces the severity and incidence of flu-like symptoms during treatment initiation.
Matson MA; Zimmerman TR; Tuccillo D; Tang Y; Deykin A
Curr Med Res Opin; 2011 Dec; 27(12):2271-8. PubMed ID: 21988668
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.
Mathew NT; Frishberg BM; Gawel M; Dimitrova R; Gibson J; Turkel C;
Headache; 2005 Apr; 45(4):293-307. PubMed ID: 15836565
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, noninferiority trial.
Pappert EJ; Germanson T;
Mov Disord; 2008 Mar; 23(4):510-7. PubMed ID: 18098274
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
Dressler D; Bigalke H; Benecke R
J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
Brin MF; Lew MF; Adler CH; Comella CL; Factor SA; Jankovic J; O'Brien C; Murray JJ; Wallace JD; Willmer-Hulme A; Koller M
Neurology; 1999 Oct; 53(7):1431-8. PubMed ID: 10534247
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
[TBL] [Abstract][Full Text] [Related]
17. A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia.
Hu W; Rundle-Gonzalez V; Kulkarni SJ; Martinez-Ramirez D; Almeida L; Okun MS; Wagle Shukla A
Parkinsonism Relat Disord; 2019 Jun; 63():195-198. PubMed ID: 30837195
[TBL] [Abstract][Full Text] [Related]
18. Application of botulinum toxin in pregnancy and its impact on female reproductive health.
Li W; Tang M
Expert Opin Drug Saf; 2020 Jan; 19(1):83-91. PubMed ID: 31868020
[No Abstract] [Full Text] [Related]
19. Grey Matter Microstructural Integrity Alterations in Blepharospasm Are Partially Reversed by Botulinum Neurotoxin Therapy.
Alexandru H; Muthuraman M; Chirumamilla VC; Koirala N; Paktas B; Deuschl G; Zeuner KE; Groppa S
PLoS One; 2016; 11(12):e0168652. PubMed ID: 27992533
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin in the treatment of rare head and neck pain syndromes: a systematic review of the literature.
Sycha T; Kranz G; Auff E; Schnider P
J Neurol; 2004 Feb; 251 Suppl 1():I19-30. PubMed ID: 14991339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
